EX-99.1 2 nari-20240930xex991xpressr.htm EX-99.1 Document
第99.1展示文本

img169044987_0a.jpg
inari medical報告2024年第三季度財務業績

加利福尼亞州爾灣愛荷華州 - 2024年10月28日 （環球新聞社）- Inari Medical, Inc.（納斯達克：NARI）（「Inari」），一家醫療器械公司 致力於治療和改善患有靜脈等疾病的患者的生活，今天報告了截至2024年9月30日的第三季度財務業績。

第三季度財務及最新業務亮點
•2024年第三季度實現營業收入15300萬美元，同比去年同期增長21%。
•2024年第三季度按照美國通用會計準則的營運虧損爲1360萬美元，相比去年同期的210萬美元營業收入。
•2024年第三季度，非通用會計淨營運虧損爲40萬美元，與去年同季度的非通用會計淨營運收入480萬美元相比。
•截至2024年Q3，現金、現金等價物和短期投資爲11200萬美元。
•獲准將PEERLESS研究作爲一項晚期臨床試驗在2024年10月29日的經皮心血管治療(TCT)年度科學研討會上報告th.

「在全球被忽視的大型血管市場中，我們繼續推動inari medical整個產品組合的強勁表現，鞏固我們在行業中的領先地位，」inari medical的首席執行官Drew Hykes說。「我們的產品表現出色，展望未來，我們在近期將迎來幾個重要的推動因素。因此，我們期待明天在轉導心血管治療（TCT）研討會上展示我們的PEERLESS數據，以及本月初獲得FDA認可後即將全面進入市場的Artix，以及在日本和中國提供inari medical解決方案的計劃。我們對以獨特目的打造的解決方案來滿足未被滿足的患者需求的使命感更加堅定。」



2024年第三季度財務結果
2024年第三季度的營業收入爲15340萬美元，比2023年第三季度的12640萬美元增長了21.4%。與去年同期相比，主要受到銷售領域擴大、新帳戶開設、我們流程採用率提高、全球商業擴張以及新產品推出的推動，而實現增長。

2024年第三季度的毛利潤爲13350萬美元，而2023年第三季度爲11190萬美元。2024年第三季度的毛利率爲87.1%，而2023年第三季度爲88.5%。年度同比變化主要是由於產品組合、新產品的投產成本和業務國際化的增加。

2024年第三季度營業費用爲14710萬美元，而2023年第三季度爲10980萬美元。主要增長原因包括與人員相關的費用，包括隨着增加的人員數量來支持商業、研發、臨床和支持組織擴張而產生的佣金和基於股票的補償；公司負債的公允價值變動；資本化的軟件減值及相關費用；包括法律費用在內的專業費用；與LimFlow收購中獲取的無形資產相關的攤銷費用；以及差旅相關費用。

2024年第三季度，根據美國通用會計準則，運營虧損爲1360萬美元，而2023年第三季度的運營收益爲210萬美元。從季度看，按順序，運營虧損改善了880萬美元。

2024年第三季度，非通用會計淨損失爲40萬美元。2023年第三季度，非通用會計淨收入爲480萬美元。按順序，非通用會計淨損失改善了1280萬美元。2024年第三季度的非通用會計淨損失中排除了以下項目：660萬美元的繼續考慮責任賬項公允價值變動、380萬美元的資本化軟件減值及相關成本、250萬美元的取得無形資產攤銷和30萬美元的收購相關費用。2023年第三季度的非通用會計淨收入中排除了270萬美元的收購相關費用。

2024年第三季度淨虧損達到1840萬美元，每股基本和攤薄權重平均股數爲5840萬，每股淨虧損達到0.31美元，相比之下，去年同期每股基本權重平均股數爲5740萬，淨利潤爲320萬美元，每股淨利潤爲0.06美元，攤薄權重平均股數爲5860萬，每股淨利潤爲0.05美元。



2024年全年營業收入展望和營業利潤前景
•Inari將2024財年營業收入指引上調至6.015億至6.045億美元，中間點相較我們之前的區間爲6.045億至6.045億美元，增長約21.9%至22.5%。
•公司仍然預計在2025年上半年實現持久的營業利潤。

網絡廣播和電話會議信息
inari medical將主持一次電話會議討論 第三 2024 財務業績將於股市閉市後討論1:30 PM太平洋時間/ 4:30 PM東部時間 2024年10月28日 ，可通過撥打(844) 825-9789（國內）或(412) 317-5180（國際）接入電話會議。 可通過訪問inari medical投資者關係網站ir.inarimedical.com的活動版塊獲取直播網絡研討會和演示。

使用非 GAAP 財務指標
本新聞稿涉及非美國通行會計原則（GAAP）覈算的非GAAP營業利潤（虧損）等條目，這被視爲非GAAP財務衡量指標。這意味着非GAAP營業利潤（虧損）是通過不符合美國通行會計原則的方法確定的。Inari使用的非GAAP營業利潤（虧損）排除了以下項目：收購的無形資產攤銷、收購相關成本、我們的待定對價負債的公允價值調整以及資本化軟件減值和相關成本，以便從GAAP營業利潤（虧損）中排除這些費用，因爲我們認爲這些費用受到收購的時間和估值，如我們於2023年第四季度完成的LimFlow收購，以及其他非經常性因素，如某些項目的結束影響顯著。我們的管理層認爲，呈現非GAAP營業利潤（虧損）是有益的，因爲它提供了有意義的與之前時期的比較，並揭示了我們的潛在經營績效，以及評估成本和費用趨勢的其他手段，排除了這些收購相關項目和其他非經常性交易的影響，這些交易與我們的核心業務運營無關。

我們對非GAAP營運虧損（虧損）的定義可能與其他人使用的類似。非GAAP營業收入（虧損）應被視爲財務信息的補充，而不是GAAP制定的財務信息的替代品。我們鼓勵投資者查看在本新聞稿中提供的非GAAP營業收入（虧損）與GAAP營業收入（虧損）的調節表，其中包括在財務報表中提供的表格。



About Inari Medical, Inc.
Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and four other targeted disease states. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram.

Forward Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements include expectations regarding Inari’s core business, plans for its current and future products, anticipated product launches, its ability to integrate and related expectations for the LimFlow acquisition, expectations regarding future growth, Inari's ability to meet customers' needs, and timing for achieving sustained operating profitability, and are based on Inari’s current expectations, forecasts, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, and actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the period ended December 31, 2023, and in Inari’s other reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are based on information available to Inari as of the date hereof and are made only as of the date of this release. Inari undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Inari’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Inari.



Investor Contact:
Marissa Bych
Gilmartin Group LLC
IR@inarimedical.com


INARI MEDICAL, INC.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share data)
(unaudited)

Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Revenue$153,390 $126,366 $442,404 $361,538 
Cost of goods sold19,846 14,477 58,732 42,062 
Gross profit133,544 111,889 383,672 319,476 
Operating expenses
Research and development29,431 21,492 81,216 64,641 
Selling, general and administrative108,271 85,603 325,479 256,889 
Change in fair value of contingent consideration
6,578 — 18,609 — 
Amortization of intangible asset
2,504 — 7,414 — 
Acquisition-related expenses
328 2,681 4,143 2,681 
Total operating expenses147,112 109,776 436,861 324,211 
(Loss) income from operations
(13,568)2,113 (53,189)(4,735)
Other income (expense)
Interest income1,104 4,202 3,371 12,899 
Interest expense(78)(43)(233)(127)
Other expense
(130)(682)(130)(617)
Total other income896 3,477 3,008 12,155 
(Loss) income before income taxes
(12,672)5,590 (50,181)7,420 
Provision for income taxes5,695 2,428 23,736 4,391 
Net (loss) income
$(18,367)$3,162 $(73,917)$3,029 
Other comprehensive income (loss)
Foreign currency translation adjustments13,918 (68)4,200 (138)
Unrealized gain (loss) on available-for-sale debt securities
64 91 60 (1,869)
Total other comprehensive income (loss)
13,982 23 4,260 (2,007)
Comprehensive income (loss)
$(4,385)$3,185 $(69,657)$1,022 
Net (loss) income per share
Basic$(0.31)$0.06 $(1.27)$0.05 
Diluted$(0.31)$0.05 $(1.27)$0.05 
Weighted average common shares used to compute net (loss) income per share
Basic58,366,36457,384,88458,149,29656,478,317
Diluted58,366,36458,588,45258,149,29658,495,921


INARI MEDICAL, INC.
Condensed Consolidated Balance Sheets
(in thousands, except share data and par value)
(unaudited)
September 30,
2024		December 31,
2023
Assets
Current assets
Cash and cash equivalents$41,141 $38,597 
Restricted cash
67 611 
Short-term investments in debt securities70,397 76,855 
Accounts receivable, net84,403 70,119 
Inventories, net55,210 42,900 
Prepaid expenses and other current assets12,168 6,481 
Total current assets263,386 235,563 
Property and equipment, net24,098 20,929 
Operating lease right-of-use assets48,301 48,407 
Goodwill213,345 214,335 
Intangible assets143,808 150,884 
Deposits and other assets4,301 4,117 
Total assets$697,239 $674,235 
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable$15,523 $10,577 
Payroll-related accruals54,797 48,706 
Accrued expenses and other current liabilities76,881 15,364 
Operating lease liabilities, current portion1,579 1,692 
Total current liabilities148,780 76,339 
Operating lease liabilities, noncurrent portion31,145 30,355 
Deferred tax liability36,748 36,231 
Other long-term liability45,805 66,400 
Total liabilities$262,478 $209,325 
Commitments and contingencies (Note 9)
Stockholders' equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2024 and December 31, 2023
— — 
Common stock, $0.001 par value, 300,000,000 shares authorized as of September 30, 2024, and December 31, 2023; 58,435,576 and 57,762,414 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively
58 58 
Additional paid in capital543,961 504,453 
Accumulated other comprehensive income
13,145 8,885 
Accumulated deficit(122,403)(48,486)
Total stockholders' equity434,761 464,910 
Total liabilities and stockholders' equity$697,239 $674,235 




INARI MEDICAL, INC.
Reconciliation of GAAP Operating Income (Loss) to Non-GAAP Operating Income (Loss)
(in thousands)
(Unaudited)

Reconciliation of GAAP Operating (Loss) Income to Non-GAAP Operating (Loss) Income:

Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
GAAP Operating (loss) income
$(13,568)$2,113 $(53,189)$(4,735)
Non-GAAP Adjustments:
Change in fair value of contingent consideration
6,578 — 18,609 — 
Amortization of acquired intangible asset
2,504 — 7,412 — 
Acquisition-related expenses (a)
328 2,681 4,142 2,681 
Capitalized software impairment and related costs (b)
3,789 — 3,789 — 
Non-GAAP Operating (loss) income
$(369)$4,794 $(19,237)$(2,054)
________________
(a) The acquisition-related expenses primarily include integration, severance and retention related expenses.
(b) The capitalized software impairment and related costs primarily include the write-off of capitalized software and related wind down costs, which were recorded within the research and development expense within the condensed consolidated statements of operations.

Revenue Disaggregation
The following tables present the amount of revenue in VTE and Emerging Therapies recognized for the periods presented (in thousands, unaudited):

Three Months Ended September 30,
20242023
% Growth
VTE$145,346 $121,460 19.7 %
Emerging Therapies8,044 4,906 64.0 %
Total Revenue$153,390 $126,366 21.4 %

Nine Months Ended September 30,
20242023
% Growth
VTE$420,213 $349,604 20.2 %
Emerging Therapies22,191 11,934 85.9 %
Total Revenue$442,404 $361,538 22.4 %